Company intelligence / Profile preview

Sensome

Ownership: Private
Employees: ~30
Development stage: Phase 1

Overview

Sensome has developed a patented micro-sensor platform that enables real-time identification and characterization of biological tissues during minimally invasive procedures. Its lead product, the Clotild® Smart Guidewire System for ischemic stroke, has received FDA Breakthrough Device Designation and completed first-in-human studies. The company’s tumor detection system for lung cancer recently completed enrollment in its first-in-human INSPECT study. No products are yet approved or commercially available as of June 2025.

Therapeutic areas: OncologyCardiovascular
Modalities: DeviceMachine learning-based diagnostic device (for tissue characterization)Micro-sensor technology platform
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Clotild

Phase 1

Indications: Ischemic stroke

Partnerships

ASAHI INTECC (manufacturing partner for Clotild® guidewire)Cosmotec (distribution partner in Japan upon approval)

Beyond the preview

Go deeper on Sensome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensome.

Explore the full profile